Application of GPER in drug target of type 2 diabetes mellitus combined with benign prostatic hyperplasia and prostatic epithelial cell proliferation

• Main Authors: QIU ZHEN, YANG TINGTING, YIN XIAOXING, PANG JIALE, LIU JUNJIE, QIAN SITONG, YUEN KATHY, HE YUTIAN, LU QIAN, JIANG ZHENZHOU
• Format: Patent
• Language: Chinese; English
• Published: 01.03.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention relates to an application of a GPER in a drug target of type 2 diabetes mellitus complicated with benign prostatic hyperplasia and prostatic epithelial cell proliferation. The research shows that the GPER possibly plays an important role in the generation and development process of T2DM combined with BPH. It is found for the first time that GPER can serve as a new molecular drug target for detecting or inhibiting T2DM combined BPH prostate epithelial cell proliferation, and the purpose of combined disease detection or drug prevention and treatment screening can be achieved by acting on the target. G15 or shRNA for specifically knocking down GPER has the potential to become a new medicine for inhibiting T2DM combined BPH prostate epithelial cell proliferation, and a new thought is provided for preventing and treating T2DM combined BPH. 本发明涉及一种GPER在2型糖尿病合并良性前列腺增生前列腺上皮细胞增殖的药物靶点的应用。研究表明GPER很可能在T2DM合并BPH发生发展过程中起着重要的作用。本发明首次发现了GPER可作为检测或抑制T2DM合并BPH前列腺上皮细胞增殖的新的分子药物靶点，可通过作用于该靶点达到合并疾病的检测或药物防治筛选的目的。G15或特异